Chargement de votre page…

Cefoxitin

10GM BASE/VIAL, 1GM BASE/VIAL, 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** … injectableÉtats-UnisCommercialiséAutorisé le 3 juil. 2000

Contenu en anglais

Ouvrir dans le registreInterroger Osler

Indications

Treatment: CEFOXITIN FOR INJECTION, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, Haemophilus influenzae , and Bacteroides species.

(2) Urinary tract infections caused by Escherichia coli, Klebsiella species, Proteus mirabilis, Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections , including peritonitis and intra-abdominal abscess, caused by Escherichia coli, Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections , including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae.

CEFOXITIN FOR INJECTION, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when CEFOXITIN FOR INJECTION, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae, Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis .

(6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli, Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger, and Peptostreptococcus species.

Deux médicaments dans une même question ?

Citez deux médicaments ou plus et Osler vérifie leurs interactions. Une interaction grave figure tout en haut de la réponse.

Découvrir Osler

Cefoxitin

Contenu en anglais

Ouvrir dans le registreInterroger Osler

Indications

Deux médicaments dans une même question ?

Citez deux médicaments ou plus et Osler vérifie leurs interactions. Une interaction grave figure tout en haut de la réponse.

Découvrir Osler

Effets indésirables

CEFOXITIN FOR INJECTION is generally well tolerated. The most common adverse reactions have been local reactions following intravenous injection. Other adverse reactions have been encountered infrequently. Local Reactions: Thrombophlebitis has occurred with intravenous administration. Allergic Reactions: Rash (including exfoliative dermatitis and toxic epidermal necrolysis), urticaria, flushing, pruritus, eosinophilia, fever, dyspnea, and other allergic reactions including anaphylaxis, interstitial nephritis and angioedema have been noted.

Cardiovascular: Hypotension. Gastrointestinal: Diarrhea, including documented pseudomembranous colitis which can appear during or after antibiotic treatment. Nausea and vomiting have been reported rarely. Neuromuscular: Possible exacerbation of myasthenia gravis. Blood: Eosinophilia, leukopenia including granulocytopenia, neutropenia, anemia, including hemolytic anemia, thrombocytopenia, and bone marrow depression. A positive direct Coombs test may develop in some individuals, especially those with azotemia.

Liver Function: Transient elevations in SGOT, SGPT, serum LDH, and serum alkaline phosphatase; and jaundice have been reported. Renal Function: Elevations in serum creatinine and/or blood urea nitrogen levels have been observed. As with the cephalosporins, acute renal failure has been reported rarely. The role of CEFOXITIN FOR INJECTION in changes in renal function tests is difficult to assess, since factors predisposing to prerenal azotemia or to impaired renal function usually have been present.

In addition to the adverse reactions listed above which have been observed in patients treated with CEFOXITIN FOR INJECTION, the following adverse reactions and altered laboratory test results have been reported for cephalosporin class antibiotics: Urticaria, erythema multiforme, Stevens-Johnson syndrome, serum sickness-like reactions, abdominal pain, colitis, renal dysfunction, toxic nephropathy, false-positive test for urinary glucose, hepatic dysfunction including cholestasis, elevated bilirubin, aplastic anemia, hemorrhage, prolonged prothrombin time, pancytopenia, agranulocytosis, superinfection, vaginitis including vaginal candidiasis.

Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced (see DOSAGE AND ADMINISTRATION ). If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated. To report SUSPECTED ADVERSE EVENTS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov .

Conditionnements

Conditionnement	Code	Statut
CEFOXITIN SODIUM EQ 10GM BASE/VIAL	ANDA065050-001	Prescription
CEFOXITIN SODIUM EQ 10GM BASE/VIAL	ANDA065312-001	Discontinued
CEFOXITIN SODIUM EQ 10GM BASE/VIAL	ANDA065239-001	Prescription
CEFOXITIN SODIUM EQ 1GM BASE/VIAL	ANDA065313-001	Discontinued
CEFOXITIN SODIUM EQ 2GM BASE/VIAL	ANDA065313-002	Discontinued
CEFOXITIN SODIUM EQ 10GM BASE/VIAL	ANDA065415-001	Prescription
CEFOXITIN SODIUM EQ 2GM BASE/VIAL	ANDA065414-002	Prescription
CEFOXITIN SODIUM EQ 1GM BASE/VIAL	ANDA065414-001	Prescription
CEFOXITIN SODIUM EQ 1GM BASE/VIAL	ANDA065051-001	Prescription
CEFOXITIN SODIUM EQ 2GM BASE/VIAL	ANDA065051-002	Prescription
CEFOXITIN SODIUM EQ 1GM BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	ANDA065012-001	Discontinued
CEFOXITIN SODIUM EQ 2GM BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	ANDA065012-002	Discontinued
CEFOXITIN SODIUM EQ 2GM BASE/VIAL	ANDA065238-002	Prescription
CEFOXITIN SODIUM EQ 1GM BASE/VIAL	ANDA065238-001	Prescription
CEFOXITIN SODIUM EQ 10GM BASE/VIAL	ANDA065464-001	Discontinued
CEFOXITIN SODIUM EQ 2GM BASE/VIAL	ANDA065467-002	Discontinued
CEFOXITIN SODIUM EQ 1GM BASE/VIAL	ANDA065467-001	Discontinued
CEFOXITIN SODIUM EQ 10GM BASE/VIAL	ANDA065011-001	Discontinued

Cefoxitin

Indications

Deux médicaments dans une même question ?

Cefoxitin

Indications

Deux médicaments dans une même question ?

Contre-indications

Mises en garde et précautions d’emploi

Interactions

Grossesse et allaitement

Effets indésirables

Dans d’autres pays

Conditionnements

Documents

Sources et licences

En bref